Our roots run deep in dermatology. In 1944, TKL Research was founded with a sole focus in dermatology. Over 70 years later, dermatology remains our specialty. Our experience and expertise are unrivaled in the clinical research community.

Phase I-II Studies

At TKL Research, our pharmacology and clinical units allow for the conduct of phase I-II studies in healthy and targeted patient populations. Multiple locations throughout the NY/NJ metro area have been strategically selected to provide us access to an extremely diverse patient population. Our metro area presence also gives us the opportunity to use the very knowledgeable NY/NJ medical community as Consulting Principal Investigators. Using our successful TKL Approach, we are able to complete your study from start to finish.


  • First in Man
  • Maximal Use
  • Dose Ranging


  • Phototoxicity
  • Photoallergy


  • Cumulative Irritation
  • Contact Sensitization (HRIPT)
  • Adhesion

Phase I IND Safety Studies 2012-2017

[wpdatachart id=1]

Patient Populations

  • Acne
  • Psoriasis
  • Rosacea
  • Actinic Keratosis
  • Atopic Dermatitis
  • Eczema
  • Tinea Curis/Tinea Pedis
  • Seborrheic Dermatitis
  • Alopecia

“We do more dermatological safety studies than any research clinic in the world.”

~ Dr. Jon Anderson, CEO – TKL Research

Dermatological Experience

  • Acne vulgaris
  • Actinic keratosis
  • Androgenetic alopecia
  • Athlete‚Äôs foot, interdigital/plantar
  • Atopic dermatitis, including HPA axis-suppression studies in pediatric/adult participants
  • Cutaneous squamous cell carcinoma
  • Dermal fillers/soft tissue contour
  • Eczema
  • External genital warts
  • Lipoma
  • Onychomycosis
  • Psoriasis, including HPA axis-suppression studies
  • Rosacea
  • Seborrheic dermatitis
  • Skin tags
  • Superficial basal cell carcinoma
  • Tinea cruris/pedis